Genzyme Corp. (NASDAQ: GENZ) today announced that the results from its Late-Onset Treatment Study (LOTS) have been published in today's New England Journal of Medicine. The study was undertaken to evaluate the safety and efficacy of Myozyme (alglucosidase alfa) in older children and adults with Pompe disease. The LOTS study was a randomized, double-blind, multi-national, placebo-controlled clinical trial that enrolled 90 older children and adults with Pompe disease... 
More...
More...